30results about How to "Good dissolution properties" patented technology

An object of this invention is to provide a cleaner for the removal of water-soluble, lead-free soldering flux, the cleaner capable of cleaning off, in a short period of time, water-soluble flux residues generated during soldering with lead-free solder using water-soluble flux, the cleaner further having excellent dissolution property as well as excellent narrow gap cleaning property. The cleaner for removing water-soluble, lead-free soldering flux of the present invention comprises 5 to 100 parts by weight of a glycol ether compound (A) per 100 parts by weight of water.

It is desired to provide a pharmaceutical composition containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof, which exhibits an inhibitory effect on activated blood coagulation factor X, and is useful as an agent for preventing and / or treating thrombosis, wherein the pharmaceutical composition exhibits favorable dissolution properties. The present invention provides a method for producing a pharmaceutical composition containing a compound represented by formula (I), comprising the step of mixing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof, one or more excipients selected from the group consisting of a sugar alcohol and a water-swelling additive, a disintegrant, and a binder under conditions for keeping the maximum water content of the granules during granulation at 10% or less.

The invention relates to an ezetimibe oral solid pharmaceutical composition, an inventor finds that an ezetimibe raw material medicine is poor in water solubility and relatively low in bioavailabilityin the research process of an ezetimibe preparation, and meanwhile, after an existing preparation is stored for a long time, an azacyclobutanone structure can be hydrolyzed to generate an open-loop impurity A; the inventor applies a surfactant solubilizing technology to the ezetimibe preparation. Bulk drug, the surfactant and the hydrophilic polymer are jointly dissolved in the solvent; when theezetimibe oral solid preparation is used for preparing a soft material, the raw material medicine and the surfactant are separated out, tightly combined and dispersed in the hydrophilic polymer at thesame time, the solubility of the medicine in water is effectively improved, and test results prove that the dissolution behavior of the ezetimibe oral solid preparation prepared through the technology is obviously improved, so that the bioavailability of the ezetimibe oral solid preparation is also improved. Meanwhile, the hydrolysis impurity A is inhibited, the stability is improved, and the preparation is simple in process, controllable in quality and suitable for industrial production.

The invention provides a hydroxychloroquine sulfate pharmaceutical preparation. The hydroxychloroquine sulfate pharmaceutical preparation comprises the following components in percentage by weight: 50-75% of hydroxychloroquine sulfate, 5-15% of mannitol, 15-35% of pregelatinized starch, 0.5-2.0% of a water-soluble adhesive and 0.5-2.0% of a lubricant. According to the hydroxychloroquine pharmaceutical preparation disclosed by the invention, the mannitol and the pregelatinized starch are used as filling agents, and are matched with the adhesive and the lubricant, so that the problem that the hydroxychloroquine pharmaceutical preparation is extremely likely to stick and the problem of poor compressibility caused by high friability of tablets can be solved, the hydroxychloroquine pharmaceutical preparation has good dissolution property, and the dissolution effect is consistent with that of a reference reagent.

A orally disintegrating tablet is obtained by tableting fine granules showing controlled release of lansoprazole and an additive, which is capable of suppressing breakage of the fine granules during tableting, and can control the release of lansoprazole for a long time, and can maintain a therapeutically effective concentration for a prolonged time, and shows superior disintegration property in the oral cavity.

The invention discloses ursolic acid pills and a preparation method thereof. The ursolic acid pills comprise an ursolic acid active ingredient and a substrate, wherein the substrate is a mixture of polyethylene glycol and poloxamer, and the mass ratio of ursolic acid to substrate is 1:(4-15). Under the cooperative and synergetic effects of different substances, the dissolution property of the ursolic acid pills is greatly improved. The dissolution rate of the prepared ursolic acid pills within 15 minutes can be up to 95% or so; thus, compared with the ursolic acid pills reported at present, the ursolic acid pills disclosed by the invention have the advantages of higher dissolution speed and higher dissolution rate; and the ursolic acid pills disclosed by the invention also have the advantages of simple preparation process, stable quality and favorable forming property, and is suitable for industrial mass production.

The present application relates to an etoposide solid pharmaceutical composition, and the inventors have finally obtained an improved etoposide solid dispersion preparation process through a series ofexperiments, and obtained an improved etoposide solid dispersion with good water solubility. Furthermore, by choosing crosslinked polyvidone with low water content (no more than 5%) as disintegratingagent of solid preparation, the water content of the preparation is effectively reduced while the disintegrating effect is exerted, and the degradation caused by absorbing the water in the preparation is inhibited. Finally, etoposide is prepared into common oral solid preparation. The results showed that the dissolution behavior and bioavailability of etoposide oral solid preparation prepared bythis technique are significantly improved. At the same time, because of choosing the auxiliary material with low water content, the degradation impurity is restrained and the stability is improved. The preparation process is simple and the quality is controllable, which is suitable for industrial production.

The invention relates to a crystal form of a compound 3-((L-valyl)amino)-1-propanesulfonic acid, a preparation method and applications thereof.

The invention provides a moxifloxacin hydrochloride pharmaceutical composition and preparation method thereof. The invention is characterized in that: tablet core is prepared by moxifloxacin hydrochloride, more than one excipient and a coating material, wherein, the weight of moxifloxacin hydrochloride is 60-70% of that of the tablet core, and the weight of excipients is 30-40% of that of the tablet core, and the weight of the coating material which is used for coating the tablet core and is composed of hypromellose with two or more than two viscosities is 1.0-4.0% of that of the pharmaceutical composition tablet core, and the weight ratio between hypromellose with viscosity of 40-120mPa.s and hypromellose with viscosity of 2.5-1.8mPa.s is 1:5-1:2. The pharmaceutical composition has the advantages of good stability, simple preparation technology and easy reproduction; the preparation method is suitable for industrial production.

The invention discloses ursolic acid pills and a preparation method thereof. The ursolic acid pills comprise an ursolic acid active ingredient and a substrate, wherein the substrate is a mixture of polyethylene glycol and poloxamer, and the mass ratio of ursolic acid to substrate is 1:(4-15). Under the cooperative and synergetic effects of different substances, the dissolution property of the ursolic acid pills is greatly improved. The dissolution rate of the prepared ursolic acid pills within 15 minutes can be up to 95% or so; thus, compared with the ursolic acid pills reported at present, the ursolic acid pills disclosed by the invention have the advantages of higher dissolution speed and higher dissolution rate; and the ursolic acid pills disclosed by the invention also have the advantages of simple preparation process, stable quality and favorable forming property, and is suitable for industrial mass production.

The present invention relates to an anti-pulmonary fibrosis composition with improved dissolution properties, comprising a salt formed of nintedanib and an acidic polymer. The salt formed by nintedanib and acidic polymer has higher solubility and certain stability. The composition of the invention can be used for oral administration, and helps the dissolution and absorption of drugs in the gastrointestinal tract.

The invention discloses a saccharin salt of rosiglitazone and a preparation method thereof. This rosiglitazone saccharin salt contains rosiglitazone cation and saccharin anion in a molar ratio of 1:1. At the same time, the preparation method of the rosiglitazone saccharin salt is also disclosed. The rosiglitazone saccharin salt is reacted in a solvent, and the rosiglitazone saccharin salt is obtained by stirring, ultrasonication, volatilization or cooling crystallization. The present invention provides a brand-new rosiglitazone saccharin salt, which has obvious advantages in the dissolution property and taste improvement of the drug, and can be applied in the pharmaceutical industry, and the preparation method is simple and the crystallization process is simple. Easy to control, good reproducibility, suitable for industrial production.

The invention discloses a pharmaceutical composition containing nitroxyquinoline prodrug, a preparation method and application thereof. The pharmaceutical composition comprises the following components in parts by weight: 100 parts of active pharmaceutical ingredients, 22.5-320 parts of fillers, 0-40 parts of disintegrants, 0-95 parts of binders and 2-30 parts of lubricants; Relative to every 100 parts by weight of the active pharmaceutical ingredient, the total amount of the filler, the disintegrant and the binder is 54-345 parts by weight; the active pharmaceutical ingredient is (S)-(5- Nitroquinoline-8-yloxy)methyl 1-isopropionylpyrrolidine-2-carboxylate. The pharmaceutical composition has good stability and dissolution properties, and has good pharmacokinetic characteristics, and can be advantageously used in the preparation and clinical application of medicines.

The present invention relates to a composition with improved dissolution properties, comprising a salt formed of a basic tinib drug molecule and an acidic polymer. The composition with improved dissolution properties comprises a salt formed of a basic tinib drug molecule and an acidic polymer, the basic tinib drug is dispersed in the acidic polymer at a molecular level to form an amorphous solid dispersion, and the base An ionic bond is formed between the tinib drug molecule and the acidic polymer, which has good stability, improves the dissolution rate and solubility of the composition, and is beneficial to be absorbed by patients.

The invention discloses a co-crystal of 5-fluorouracil and kaempferol and a preparation method thereof. The molar ratio of 5-fluorouracil and kaempferol in the eutectic is 1:1, and the X-ray powder diffraction pattern of the eutectic is 12.2±0.2°, 13.9±0.2°, 14.8±0.2°, 16.5±0.2°, There are characteristic peaks at 17.5±0.2° and 26.7±0.2°. The eutectic preparation method provided by the invention has simple process, easy control of the crystallization process, good reproducibility, and is suitable for industrial production. This co-crystal can effectively reduce the hygroscopicity of kaempferol, optimize the dissolution properties of 5-fluorouracil and kaempferol, reduce the difference in solubility between the two, improve the compatibility of the preparations of the two drugs, and provide better performance for the two drugs. Anti-tumor synergy provides a research basis.